Wart Remover Patch

Description

Wart Remover Patch 1 is a topical dosage form designed for the removal of warts. The patch is specifically formulated to deliver active ingredients directly to the affected area, facilitating the treatment process. The product is characterized by its adhesive backing, which ensures secure application to the skin. The appearance of the patch is consistent with standard medical adhesive patches, allowing for ease of use in various settings.

Uses and Indications

This drug is indicated for the removal of warts.

There are no specific teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to administer one patch per day. Each patch contains 1 mg of tolnaftate. The patch should be applied to clean, dry skin, ensuring that it adheres properly. It is important to rotate the application site to minimize skin irritation. The patch should not be applied to broken or irritated skin.

Contraindications

Use of this product is contraindicated in the following situations:

Application is not recommended on irritated, infected, or reddened skin due to the potential for exacerbating the condition. The product should not be applied to genital warts or warts located on the face, as these areas may be sensitive and require specialized treatment. Additionally, the use of this product is contraindicated on moles, birthmarks, and warts with hair growing from them, as these may indicate underlying conditions that necessitate caution. Finally, application to mucous membranes is contraindicated due to the risk of irritation and adverse reactions.

Warnings and Precautions

For external use only. It is imperative to keep this product out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

This product should not be applied to irritated, infected, or reddened skin. Additionally, it is contraindicated for use on genital warts, warts located on the face, moles, birthmarks, and warts with hair growing from them. Application to mucous membranes is also prohibited.

Healthcare professionals should advise patients to consult a physician prior to use if they have diabetes or experience poor blood circulation, as these conditions may necessitate additional precautions or monitoring.

Side Effects

For external use only. No specific adverse reactions have been reported in clinical trials or postmarketing experiences. It is essential for patients to adhere to the recommended usage guidelines to minimize the risk of potential adverse effects.

Drug Interactions

There are no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. Therefore, no specific dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Wart Remover Patch (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no specific information regarding the use of WART REMOVER PATCH (salicylic acid patch) during pregnancy. The prescribing information does not provide safety concerns, dosage modifications, or special precautions for pregnant patients. Therefore, healthcare professionals should exercise caution when considering the use of this product in pregnant women, as the potential risks and effects on fetal outcomes are not well characterized. It is advisable to weigh the benefits against any unknown risks when treating women of childbearing potential.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there are no statements concerning the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment may require dosage adjustments to ensure safety and efficacy. It is essential to monitor renal function tests in these individuals to assess their kidney status. Additionally, a reduced dose should be considered for patients with decreased creatinine clearance to mitigate the risk of adverse effects associated with impaired renal function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring adequate circulation. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and is deemed appropriate based on clinical judgment.

Additionally, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management protocols and antidotes, if applicable. Continuous monitoring and reassessment of the patient's condition are vital to ensure optimal outcomes.

In summary, while specific overdosage information is not available, healthcare professionals should remain vigilant and prepared to implement standard overdose management strategies.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. It is important to emphasize that if the medication is swallowed, patients should seek medical help or contact a Poison Control Center immediately. This guidance is crucial for ensuring the safety and well-being of patients and their families.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within the temperature range of 59° to 86°F (15° to 30°C) to maintain its efficacy and integrity. Proper storage conditions must be adhered to, ensuring that the product is kept in a suitable container that protects it from environmental factors. Special handling requirements should be observed to prevent any compromise to the product's quality.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Wart Remover Patch, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)